

## Special Issue

# Advances and Application of Cryo-Electron Microscopy in Molecular Biology and Biomedicine

### Message from the Guest Editors

**Cryo-electron microscopy (cryo-EM)** has emerged as a powerful tool for visualizing the structures of biological macromolecules and complexes with unprecedented detail. This Special Issue aims to present the forefront of cryo-EM research, focusing on advancements that have significantly improved data quality, resolution, and throughput. In particular, the integration of artificial intelligence (AI) techniques such as deep learning algorithms has revolutionized cryo-EM data analysis, enabling more accurate and efficient interpretation of complex structures. Contributions to this Special Issue will cover a wide range of topics, including, but not limited to, sample preparation methodologies, hardware innovations, image processing algorithms, and applications in molecular biology and biomedicine. By highlighting recent breakthroughs and discussing future directions, this Special Issue seeks to inspire further innovation and collaboration in the field of cryo-EM.

### Guest Editors

Dr. Yue Wang

1. Innovation Center for Brain Medical Sciences of the Ministry of Education, Huazhong University of Science and Technology, Wuhan 430030, China

2. Department of Molecular and Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Dr. Renbin Yang

Laboratory of Molecular Biology, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA

### Deadline for manuscript submissions

closed (31 March 2025)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/203853](https://mdpi.com/si/203853)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).